LY2510924 Clinical Trials

Size	Price	Qty
2mg	USD 170
5mg	USD 317

Clinical Trials

Multiple clinical trials have evaluated LY2510924 across Phase 1 and Phase 2 studies, exploring its therapeutic potential in advanced solid tumors, leukemia, metastatic clear cell renal cell carcinoma, and extensive-stage small cell lung carcinoma. Sponsored by entities such as Eli Lilly and Company, AstraZeneca, M.D. Anderson Cancer Center, and the High Impact Clinical Research Support Program, these investigations evaluated LY2510924 as monotherapy or combined with chemotherapy or immunotherapy. All trials have reached completed or terminated recruitment statuses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02652871	COMPLETED	Leukemia	M.D. Anderson Cancer Center	2016-05-09	PHASE1
NCT02737072	TERMINATED	Solid Tumor	Eli Lilly and Company	2016-09	PHASE1
NCT02737072	Terminated	Solid Tumor	Eli Lilly and Company\|AstraZeneca	2016-09	Phase 1
NCT02652871	Completed	Leukemia	M.D. Anderson Cancer Center\|Eli Lilly and Company\|High Impact Clinical Research Support Program	2016-05-09	Phase 1
NCT01391130	TERMINATED	Metastatic Clear Cell Renal Cell Carcinoma	Eli Lilly and Company	2011-08	PHASE2
NCT01439568	COMPLETED	Extensive Stage Small Cell Lung Carcinoma	Eli Lilly and Company	2011-09	PHASE2

(data from https://clinicaltrials.gov, updated on 2019-11-15)

Check the LY2510924 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

LY2510924 functions as a potent and selective CXCR4 antagonist that competitively blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nmol/L, thereby suppressing SDF-1-induced GTP-binding and downstream intracellular signaling cascades. This pathway blockade disrupts CXCR4-mediated cell trafficking, adhesion, and survival within the tumor microenvironment, providing a therapeutic rationalization for its evaluation in clinical trials for solid tumors, leukemia, renal cell carcinoma, and small cell lung carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).